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Leukoaraiosis, intracerebral hemorrhage,
and functional outcome after acute stroke
thrombolysis
ABSTRACT
Objective: To perform a systematic review and pooled meta-analysis of published studies to assess
whether the presence of leukoaraiosis on neuroimaging before treatment with thrombolysis (IV or
intra-arterial) is associated with an increased risk of symptomatic intracerebral hemorrhage (sICH)
or poor functional outcome.
Methods: We included studies of patients with acute ischemic stroke, treated with IV or intra-
arterial thrombolysis, which assessed functional outcome (3-month modified Rankin Scale
[mRS]) or sICH in relation to leukoaraiosis on pretreatment neuroimaging (CT or MRI). We used
random-effects models to calculate pooled relative risks (RR) of sICH and poor functional outcome
(mRS $ 2) for any vs no leukoaraiosis (using any rating scale) and for no to mild vs moderate to
severe leukoaraiosis (using the Van Swieten or Fazekas Schmidt scale).
Results:We identified 15 studies (total n5 6,967). For sICH outcome, the RRwas 1.65 (n5 5,551;
95% confidence interval [CI] 1.26–2.16, p5 0.001) with an absolute risk (AR) increase of 2.5% for
any leukoaraiosis vs none. The RR was 2.4 (n5 4,192; 95% CI 1.83–3.14, p5 0.001) with an AR
increase of 6.2% formoderate to severe vs no tomild leukoaraiosis. For poor functional outcome; the
RR was 1.30 (n 5 3,401; 95% CI 1.19–1.42, p 5 0.001) with an AR increase of 15.4% for any
leukoaraiosis vs none. The RR was 1.31 (n 5 3,659; 95% CI 1.22–1.42, p 5 0.001) with an AR
increase of 17.5% for moderate to severe vs no to mild leukoaraiosis. No statistical heterogeneity
was noted for any of the analyses.
Conclusions: Leukoaraiosis presence and severity are consistently associated with an increased
risk of sICH and poor functional outcome after IV or intra-arterial thrombolysis for acute ischemic
stroke. Neurology® 2017;88:638–645
GLOSSARY
CI 5 confidence interval; ICH 5 intracerebral hemorrhage; LA 5 leukoaraiosis; mRS 5 modified Rankin Scale; RCT 5
randomized control trial; RR 5 relative risk; sICH 5 symptomatic intracerebral hemorrhage; tPA 5 tissue plasminogen
activator.
Thrombolytic therapy in acute ischemic stroke increases the risk of intracerebral hemorrhage
(ICH).1 Symptomatic ICH (sICH) occurs in 2.4%–10% of patients within 24–36 hours after
thrombolysis2–4 and is associated with an increased risk of subsequent death or disability.5
Imaging markers of small vessel disease, e.g., leukoaraiosis (LA) and cerebral microbleeds, are
potential risk factors for thrombolysis-related ICH6,7 and poor clinical outcome.8,9
On plain CT, LA is denoted by bilateral (patchy or diffuse) areas of hypodensities in the
periventricular white matter regions, which may extend to the centrum semiovale.10 On MRI,
LA is seen on T2-weighted magnetic sequences as hyperintense signal, termed white matter
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hyperintensities of presumed vascular origin.10
LA is primarily attributed to cerebral small vessel
disease, causing chronic ischemic damage
through disturbance of the microcirculation;
LA has variable severity but typically progresses
gradually over time, with the accumulation of
vascular risk factors and advancing age.7 Data
regarding the association between LA and sICH
have been conflicting, with some studies report-
ing an increased risk of sICH and poor clinical
outcome following thrombolysis for acute ische-
mic stroke,7,9,11–14 and others not.15–18 We there-
fore performed a systematic review and pooled
meta-analysis of published studies to assess the
evidence whether the presence of LA on neuro-
imaging before treatment with thrombolysis
(IV/intra-arterial) is associated with an increased
risk of sICH and poor functional outcome.
METHODS Search strategy and selection criteria. We
searched MEDLINE and EMBASE between January 1, 1995,
and September 1, 2015, using the following search terms: leukoar-
aiosis or white matter or small vessel disease(s) (SVD) in association
with thromboly* or tPA or tissue plasminogen activator or
fibrinoly*. We identified further studies from reference lists from
publications and identified from the above search terms. We did not
limit the search to any language. Case reports were excluded.
Eligibility criteria. Prospective or retrospective studies, which
assessed sICH risk or functional outcome and rated LA on
pretreatment CT or MRI in patients with acute ischemic stroke
treated with thrombolysis, were included.
Data extraction. Two authors (K.K. and D.W.) read the
abstracts of selected potentially relevant studies, reviewed the full
text of those that appeared relevant, and extracted data indepen-
dently. Both authors identified and read each study and resolved
any differences by discussion with a third author (D.J.W.). We
extracted information on type of study, number and characteris-
tics of participants (including mean age and sex), neuroimaging
parameters, duration of follow-up, number of participants with
LA, number of participants with the outcome event (sICH
defined according to standard criteria), and functional outcome.
Consensus on the final studies included was reached by
discussion. Where data were not available on LA, sICH, and
the functional outcome, we contacted the study authors to
request aggregate-level data. A flow chart of study selection is
provided in figure e-1 at Neurology.org. Where all appropriate
data were not extractable from the published articles, we
contacted each study group to provide all required data for our
analysis.
Quality assurance. We followed the Strengthening the Report-
ing of Observational Studies in Epidemiology as quality indicators19
and we prepared the article with reference to Meta-analyses of
Observational Studies guidelines.20
LA definition and statistical analysis. LA severity was
defined using various scales: the Gorter scale21; the van Swieten
scale22; the Blennow rating scale23; the Wahlund rating scale24;
the Fazekas scale25; the Fazekas and Schmidt (2003)26 scale; the
Fazekas and Schmidt (1992) scale27; and the Scheltens score
scale.28 Although combining scales potentially introduces hetero-
geneity, the good correlation for presence/absence and different
severity grades among the different visual rating scales allows
meaningful comparison of the results.29 Based on the findings
reported, we first compared outcomes between the presence of
any LA vs no LA; second, we compared outcomes between no to
mild LA vs moderate to severe LA. We pooled data for both of
these comparisons in separate meta-analyses.
For the sICH outcome (no LA vs any LA), we were able to
combine all of the different scales, as no LA was defined the same
regardless of scale (10 articles).11–18,30,31 Eight studies provided
sICH risk between patients with no to mild LA vs moderate to
severe LA; 26,32 of 8 studies used the Fazekas and Schmidt 2003
(scores 0–1 defined as no to mild and 2–3 as moderate to severe).
A total of 67,12–14,16,31 of 8 studies used van Swieten (scores 0–2
defined as no to mild and 3–4 defined as moderate to severe).
For functional outcome at 3 months, the same analyses as
above were undertaken: no vs any LA (8 articles)9,13–16,18,31,33
and no to mild vs moderate to severe (van Swieten22) (6
articles).7,9,13,14,16,31
We used a random-effects model to calculate the pooled rel-
ative risk (RR) of sICH and functional outcome in patients with
vs without LA; weights were calculated using the inverse variance
method. We assessed heterogeneity using I2 and x2 statistics indi-
cating the percentage of variance in a meta-analysis attributable
to study heterogeneity and through visual inspection of the
forest plots. We explored publication bias with funnel plots.
We calculated pooled absolute risk between each group comparing
any LA vs no LA and moderate to severe LA vs no to mild LA.
Meta-analyses were performed using Stata 11.2 (StataCorp LP,
College Station, TX).
RESULTS We identified 667 articles in our initial
search of MEDLINE and EMBASE; 19 studies met
our inclusion criteria. Nine articles provided the
required data and we e-mailed the authors of the
Table 1 Pooled relative risk for symptomatic intracerebral hemorrhage (sICH)
and poor functional outcome
LA distribution
Pooled absolute event
rates, n/N (%)
Pooled absolute
risk increase, %
Pooled
RR
Lower
95% CI
Upper
95% CI
sICH
No LA 115/2,779 (4.1) 2.5 1.65 1.26 2.16
LA 184/2,772 (6.6)
sICH
No to mild LA 140/3,470 (4.0) 6.2 2.40 1.83 3.14
Moderate to
severe LA
74/722 (10.2)
Poor functional
outcome
No LA 839/1,594 (52.6) 15.4 1.30 1.19 1.42
LA 1,230/1,807 (68.0)
Poor functional
outcome
No to mild LA 1,803/3,079 (58.5) 17.5 1.31 1.22 1.42
Moderate to
severe LA
441/580 (76.0)
Abbreviations: CI 5 confidence interval; LA 5 leukoaraiosis; RR 5 relative risk.
Pooled relative risk for sICH and poor functional outcome (modified Rankin Scale score $2
at 3 months) for different LA burden.
Neurology 88 February 14, 2017 639
ª 2017 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
remaining 10 articles to obtain the required data.
Four articles (831 patients in total) were unable to
provide functional outcome data. We included data
from 15 articles including a total of 6,967 patients.
The number of patients with LA was 2,934, giving
an overall pooled prevalence of 42.1%. A flow chart
of study selection is shown in figure e-1. A summary
of the characteristics of included studies is provided in
tables e-1–e-5. Not all LA measures or outcomes were
available from all studies; therefore different numbers
of participants contributed to each analysis as
described in detail below.
sICH risk. For this analysis, we included data from 10
articles11–18,30,31 including 5,551 patients comparing
sICH risk post thrombolysis between patients with
no LA vs any LA. The total sICH rate was 299/5,551
(5.4%). The sICH event rate in those with any LA
was 6.6% vs 4.1% for those without LA; thus, any LA
confers an absolute risk increase of 2.5% for sICH.
The pooled RR of sICH risk was 1.65 (95% confi-
dence interval [CI] 1.26–2.16; p 5 0.001) in those
with LA vs those without (figure 1). Heterogeneity
(I2) was 28.0% between the studies. In meta-
regression, 3 factors accounted for the heterogeneity
as assessed by I2: initial stroke severity (NIH Stroke
Scale score), type of imaging (CT or MRI), and use of
endovascular treatment. However, none of these
variables was statistically associated with the outcome
of interest (sICH). There was no evidence of
publication bias in the funnel plot (figure e-2).
Eight studies6,7,9,13,14,16,31,32 including 4,192 pa-
tients compared sICH risk post thrombolysis between
patients with no to mild LA and moderate to severe
LA. The total sICH rate was 214/4,192 (5.1%). The
sICH event rate in those with moderate to severe LA
was 10.2% vs 4.0% for those no to mild LA; thus,
moderate to severe LA confers an absolute risk
increase of 6.2% for sICH (table 1). The pooled
RR of sICH risk post thrombolysis was 2.40 (95%
CI 1.83–3.14; p5 0.001) for those with moderate to
severe vs no to mild LA (figure 2). There was no
significant heterogeneity between studies (I2 was
0%). There was no evidence of publication bias in
the funnel plot (figure e-2).
Functional outcome. For this analysis, data were avail-
able from 11 studies including a total of 5,823 pa-
tients. A summary of the characteristics of included
studies is provided in tables e-1–e-5. Of the 11 avail-
able studies, 97,9,13–16,18,31,33 provided data on poor
functional outcome as modified Rankin Scale
(mRS) score $2 at 3 months. Two articles provided
different outcomes (the ISTc group17 reported the
Figure 1 Forest plot of symptomatic intracerebral hemorrhage (sICH): Any leukoaraiosis (LA) vs no LA
Forest plot of sICH-associated LA in post-thrombolysis patients: any LA vs no LA. CI 5 confidence interval; RR 5 relative risk.
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Oxford Handicap scale $3 at 6 months and Shi
et al.32 reported mRS $3 at discharge) so could not
be included in the meta-analysis.
Eight articles, including 3,401 patients, compared
3-month outcome between patients with no LA vs
any LA. The total poor functional outcome rate was
2,069/3,401 (60.8%). The poor functional outcome
event rate in those with any LA was 68.0% vs 52.6%
for those without LA; thus, any LA confers an abso-
lute risk increase of 15.4% for poor functional
outcome (table 1). The pooled RR of poor functional
outcome was 1.30 (95% CI 1.19–1.42; p 5 0.001)
for those with any LA vs those without (figure 3).
Heterogeneity (I2) was 13.7% between the studies.
In meta-regression, 3 factors accounted for heteroge-
neity as assessed by I2: hypertension, use of endovas-
cular treatment, and initial stroke severity (NIH
Stroke Scale score). However, none of these variables
was statistically associated with clinical outcome at 3
months. There was some evidence of publication bias
in the funnel plot (figure e-2).
Six articles, including 3,659 patients, compared
outcome at 3 months between no to mild LA
and moderate to severe LA. The total poor functional
outcome rate was 2,244/3,659 (61.3%). The poor
functional outcome event rate in those with moderate
to severe LA was 76.0% vs 58.5% for those no to
mild LA; thus, moderate to severe LA confers an abso-
lute risk increase of 17.5% for poor functional out-
come (table 1). The pooled RR of poor functional
outcome was 1.31 (95% CI 1.22–1.42; p 5 0.001)
for those with moderate to severe LA vs no to mild LA
(figure 4). Heterogeneity (I2) was 13.2% between the
studies. In meta-regression, 2 factors accounted for
heterogeneity as assessed by I2: hypertension and
sex. However, neither of these variables was statisti-
cally associated with clinical outcome at 3 months.
There was no evidence of publication bias in the
funnel plot (figure e-2).
DISCUSSION Our systematic review and meta-
analysis shows that the presence of LA on
pretreatment neuroimaging is associated with an
increased risk of sICH and poor functional outcome
following thrombolytic treatment. Pooled analyses
show that both presence and greater severity of LA
are associated with a greater risk of sICH.
Our findings have biological plausibility. LA indicates
presumed ischemic white matter injury in the territory of
the penetrating small vessels in the distal deep arterial or
arteriolar territories, associated with chronic endothelial
dysfunction, and disruption of the blood–brain bar-
rier.34 The increased risk of sICH after thrombolysis may
be explained by damage to the cerebral microcirculation
Figure 2 Forest plot of symptomatic intracerebral hemorrhage (sICH): Moderate to severe leukoaraiosis (LA) vs no to mild LA
Forest plot of sICH-associated LA in post-thrombolysis patients: moderate to severe LA vs no to mild LA. CI 5 confidence interval; RR 5 relative risk.
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causing increased small vessel fragility and susceptibility
to vessel rupture and bleeding complications.11 In
addition, LA is associated with platelet hyperactivation
and hypercoagulability,35 which might reduce tissue
perfusion after thrombolysis, leading to increased
hemorrhagic transformation of the infarct.
Our pooled analyses show that both presence and
greater severity of LA are associated with a poor func-
tional outcome. LA might plausibly be relevant for
stroke functional recovery: it is associated with cortical
neuronal death, white matter disconnection that might
result in decreased cerebral plasticity, and impaired
learning during neurorehabilitation.36 Intact network
connectivity of the brain is a critical factor for recovery
from ischemic damage after acute stroke,15 which
might be impaired by LA causing demyelination, loss
of axons and oligodendrocytes, and astrocytic gliosis.37
Thus, due to these multiple mechanisms, LA could be
related to increased risk of haemorrhage, delayed recov-
ery, and impaired plasticity with poorer poststroke
functional outcome.37 LA is also a risk factor for devel-
oping poststroke cognitive impairment, depression,
difficulties in walking, and urinary incontinence that
may eventually adversely affect patients’ compliance
with treatment and recovery programs.38
Our study has several strengths. We included a large
number of patients. We undertook meta-regression
to assess for heterogeneity and confounding. Fur-
thermore, undertaking separate meta-analyses on
no vs any LA and no to mild vs moderate to severe
LA allows us to demonstrated a dose-response effect
with a higher risk of sICH in those with more severe
LA, which supports a biologically plausible causal
association. Finally, our results are consistent with
those from studies excluded from the meta-analysis
as they measured functional outcome with different
scales or time points.
There are some limitations of our analyses. First,
the neuroimaging varied between studies, and
included both CT and MRI, which is likely to affect
the prevalence of LA. Nevertheless, our study shows
that medium to high scores on ordinal scales indicat-
ing moderate to severe LA (easily detected on CT)
carry a high risk of sICH risk compared to those with
no to mild LA. This suggests that CT is sufficient to
detect clinically relevant LA associated with increased
sICH risk and poor functional outcome. Second,
there was heterogeneity in thrombolysis protocols
and the availability of some baseline characteristics;
for example, hypertension, hyperglycemia, prior use
of antiplatelet and anticoagulant medications, or
recurrent stroke. Third, definitions in sICH varied,
although we partially accounted for this heterogeneity
by meta-regression. Fourth, there is likely to be
Figure 3 Forest plot of poor functional outcome: Any leukoaraiosis (LA) vs no LA
Forest plot of modified Rankin Scale score$2 at 3months associated with LA in post-thrombolysis patients: any LA vs no LA. CI5 confidence interval; RR5
relative risk.
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selection bias in studies using MRI since unwell pa-
tients are more likely to be excluded, although the
use of CT or MRI did not appear to be associated
with any significant difference in the occurrence of
sICH or poor functional outcome. Finally, we have
not investigated the effect of ethnicity, which might
be relevant for LA prevalence and sICH risk.
The poorer functional outcome in those with LA is
likely to be due in part to the increased risk of sICH,
particularly in those with moderate to severe LA, in
whom the absolute risk was 6.2% higher than in those
with no to mild LA. This association begs the question
of whether thrombolysis should be withheld in patients
with moderate to severe LA. All patients in our analysis
were treated with thrombolysis, so we do not know the
outcome in patients with or without LA where throm-
bolysis was withheld based on clinical judgement
(which might have included an assessment of severe
LA), so we cannot assess for interaction between LA
and thrombolysis. In other words, the current study
cannot determine whether those with moderate to
severe LA would still derive benefit from thrombolysis
treatment. Accordingly, our findings do not justify
withholding thrombolytic therapy in patients with
LA. Nevertheless, subanalysis of a randomized con-
trolled trial shows that the beneficial effect of thrombol-
ysis on favorable functional outcome (mRS 0–1) was
only experienced in those without LA.16 Thus, our
results might justify the need for future randomized
control trials (RCTs) of thrombolysis to include
stratification of patient outcomes by pretreatment LA.
Until such time, other treatment options for those with
moderate to severe LA with concern about high sICH
risk include endovascular treatment (where a small
unadjusted case series saw no difference in sICH rates
according to LA grade)39 or lower dose tissue plasmin-
ogen activator (tPA),40 although there is currently no
clear evidence supporting the latter strategy; subgroup
analyses of the interaction of tPA dose and pretreatment
LA in a recent RCT40 will be of considerable interest.
Our analysis suggests an approximate doubling
of the risk of sICH after thrombolysis for acute
ischemic stroke if LA is present on pretreatment
neuroimaging; the risk is highest for moderate to
severe LA, which is easily detected on plain CT im-
ages. Importantly, LA is also associated with
increased risk of poor functional outcome after
thrombolysis therapy. However, in the absence of
randomized trial data, our results do not justify
withholding thrombolytic therapy from otherwise
eligible candidates solely on the basis of LA presence
on neuroimaging. Nevertheless, these data may be
useful for clinicians in assessing likely sICH risk
and functional outcome in individual patients, and
for counseling patients and families about the
expected outcome of thrombolytic therapy.
Figure 4 Forest plot of poor functional outcome: Moderate to severe leukoaraiosis (LA) vs no to mild LA
Forest plot of modified Rankin Scale score $2 at 3 months associated with LA in post-thrombolysis patients: moderate to severe LA vs no to mild LA. CI 5
confidence interval; RR 5 relative risk.
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This Week’s Neurology® Podcast
Prognosis of carotid dissecting aneurysms: Results from
CADISS and a systematic review (see p. 646)
This podcast begins and closes with Dr. Robert Gross, Editor-in-
Chief, briefly discussing highlighted articles from the February
14, 2017, issue of Neurology. In the first segment, Dr. Andy
Southerland interviews Dr. Hugh Markus about his paper on
the prognosis of carotid dissecting aneurysms. Dr. Robert Gross
talks with Dr. Brian Callaghan and Dr. Kevin Kerber about
Innovations in Care Delivery, one of two new Neurologyminisites,
for our “What’s Trending” feature of the week. In the next part
of the podcast, Dr. Ted Burns focuses his interview with Dr. John Noseworthy on a Neurology
Today® story titled At the Helm: The Neurologist as National Health Care Leader: Mayo Clinic’s John
M. Noseworthy, MD.
Disclosures can be found at Neurology.org.
At Neurology.org, click on “RSS” in the Neurology Podcast box to listen to the most recent
podcast and subscribe to the RSS feed.
CME Opportunity: Listen to this week’s Neurology Podcast and earn 0.5 AMA PRA Category
1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.
Neurology 88 February 14, 2017 645
ª 2017 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
